5 research outputs found
A Modified Method for Increasing Radiochemical Purity of I-125 for Radiopharmaceuticals
No full textIodine-125 (125I) is one of the radioisotopes widely used in radiopharmaceuticals for diagnosis and therapy of various cancers. Recent reports indicate that there has been shortages in the world supply of this radioiodine isotope. One of the absolute requirements good radiopharmaceuticals must meet is radiochemical purity, which generally has to be above 95 %, with an efficiency of over 90 %. The previous investigation shows that the radiochemical purity is low and does not meet the radiochemical requirement. In this work, we aim at improving the previous method by modifying the Jones reductor-based method. The modified method includes reduction and uniformization of Zn particle sizes, Zn particle compaction, and the performance of reduction process in a closed process flow. The Jones reductor converted impurities into products; in this case, iodate (IO3-) and periodate (IO4-) impurities were converted into iodide (I-), so that 125I product fulfills the radiochemical purity requirements and yielded high efficiency. In this investigation, the 125I previous product was, for the first time, improved with a radiochemical purity of 99.24 % and an efficiency of 97.98 %
Peningkatan Kemurnian Radiokimia Iodium-125 Produksi PRR dengan Natrium Metabisulfit dan Reduktor Jones
No full textRadioisotop 125iodium cukup dikenal luas manfaatnya, diantaranya adalah sebagai perunut (tracer) kit RIA/IRMA untuk deteksi in-vitro berbagai penyakit, sebagai sumber radiasi dalam brachytherapy penyakit kanker, sebagai perunut binding assay dalam berbagai penelitian bioteknologi. Beberapa tahun lalu untuk memenuhi kebutuhan dalam negeri 125I masih diimpor. BATAN, telah memiliki fasilitas produksi radioisotop 125I, tetapi sampai dua tahun terakhir selain efisiensi produksi belum optimal, kualitas produk belum memenuhi persyaratan untuk banyak keperluan di atas. 125I yang digunakan pada bidang kesehatan dalam bentuk larutan Na125-I harus memiliki kemurnian radiokimia tinggi (>95 %) agar mendapatkan hasil penandaan yang baik. Dengan demikian perlu dilakukan peningkatan kemurnian radiokimia 125I- dengan mengurangi pengotor radiokimia yang berasal pengotor ion iodat dan ion periodat. Pada penelitian ini digunakan Na2S2O5 dan reduktor Jones untuk mereduksi ion iodat dan ion periodat menjadi ion iodida. (Na125-I) produksi PRR-BATAN sampai batas yang diharapkan. Pada percobaan ini diperoleh kemurnian radiokimia 125I- 91,49 % dengan penambahan Na2S2O5 0,1 N volume 6 uL, dan 95,16% dengan volume 8 uL. Penggunaan Na2S2O5 dengan konsentrasi 0,3 N volume 2 uL diperoleh kemurnian radiokimia 99 % sedangkan volume 4 uL, 6 uL, dan 8 uL menghasilkan kemurnian radiokimia 100 %. Sedangkan penggunaan reduktor Jones menghasilkan kemurnian radiokimia 125I- yaitu 99,83 %.
Kata Kunci: iodium-125, kemurnian radiokimia, Na2S2O5, reduktor Jones, iodat
Preparasi Radiofarmaka 99mTc-Etambutol Untuk Deteksi Tuberkulosis
No full textPreparation Of 99mTc- ETAMBUTOL Radiopharmaceutical For Detection Of Tuberculosis. Radiopharmaceutical is a radioactive compound used for health services in nuclear medicine. Most of radiopharmaceutical was used for diagnosis of various abnormalities of organs, such as for the detection of tuberculosis. Tuberculosis (TB) is an infection disease caused by mycobacterium tuberculosis and can attack various organs of the body, which can lead to death. By using nuclear technology Batan has been developing ethambutol radiopharmaceutical labeled with 99mTc for detection of extra lung tuberculosis with results more sensitive and accurate that are not easily detected by methods and equipment used today and the aims to fulfil radiopharmaceuticals for hospital because there is no availability of ethambutol kits on the market. The etambutol kit produced by dry lyophilized method in sterile room, therefore has to fulfil requirements as a radiopharmaceutical. The Quality Control was performed by using several parameters including sterility , endotoxin and radiochemical purity. The results of quality control showed that Etambutol was sterile, endotoksin requirments and radiochemical purity on average >85 %. Result of clinical test from hospital showed that the image was very clear and contrast , 99mTc-ethambutol was uptake with Mycobacterium tuberculosis and accumulated in organs infected of TB
Preparasi Radiofarmaka 99mTc-Etambutol Untuk Deteksi Tuberkulosis
No full textPreparation Of 99mTc- ETAMBUTOL Radiopharmaceutical For Detection Of Tuberculosis. Radiopharmaceutical is a radioactive compound used for health services in nuclear medicine. Most of radiopharmaceutical was used for diagnosis of various abnormalities of organs, such as for the detection of tuberculosis. Tuberculosis (TB) is an infection disease caused by mycobacterium tuberculosis and can attack various organs of the body, which can lead to death. By using nuclear technology Batan has been developing ethambutol radiopharmaceutical labeled with 99mTc for detection of extra lung tuberculosis with results more sensitive and accurate that are not easily detected by methods and equipment used today and the aims to fulfil radiopharmaceuticals for hospital because there is no availability of ethambutol kits on the market. The etambutol kit produced by dry lyophilized method in sterile room, therefore has to fulfil requirements as a radiopharmaceutical. The Quality Control was performed by using several parameters including sterility , endotoxin and radiochemical purity. The results of quality control showed that Etambutol was sterile, endotoksin requirments and radiochemical purity on average >85 %. Result of clinical test from hospital showed that the image was very clear and contrast , 99mTc-ethambutol was uptake with Mycobacterium tuberculosis and accumulated in organs infected of TB
Synthesis and Characterization of Poly(Amidoamine) Dendrimers Encapsulated 198Au Nanoparticles
No full textBrachytherapy or internal radiotherapy is one of many methods used for treatment of cancer. This modality requires an agent with radionuclides that emits α or β particle with a proper energy. 198Au (99% β max = 0.96 MeV and t1/2 = 2.69 days) is one of radionuclides that has been considered to be effective for the above-mentioned purpose. The purpose of this research was to synthesis and characterize poly(amidoamine) (PAMAM) G3.0 dendrimers encapsulated 198Au nanoparticles as a new brachytherapy agent. PAMAM G3.0 dendrimers encapsulated 198Au nanoparticles was successfully synthesized by a bottom-up method using sodium borohydride as a reductor. Purification was then performed by a size exclusion chromatography in order to separate large Au nanoparticles that were formed outside the cavity of PAMAM G3.0 dendrimers. Prior to the synthesis of PAMAM G3.0 dendrimers encapsulated 198Au nanoparticles, the synthetic procedure was first established by using a non-radioactive Au. The PAMAM G3.0 dendrimers encapsulated Au nanoparticles produced was then characterized by using an UV-Vis spectroscopy, a transmission electron microscopy (TEM), particle size analyzer (PSA), and an atomic absorption spectroscopy (AAS). Characterization results revealed that PAMAM G3.0 dendrimers encapsulated Au nanoparticles that were prepared from a reaction mixture of PAMAM G3.0 dendrimers and Au HAuCl4 with mol ratio of 2.8, was found to be a proper formula. It produced PAMAM G3.0 dendrimers encapsulated Au nanoparticles with diameter of 1.743 nm, spheris, uniform and drug loading value of 26.34%. This formula was then used in synthesis using radioactive Au, 198Au. Characterization results of PAMAM G3.0 dendrimers encapsulated 198Au nanoparticles gave a radiochemical purity of 99.4% and zero charge. Received: 04 December 2012; Revised: 18 December 2012; Accepted: 20 December 201
